titles and abstracts of the reports identified via the search strategies described earlier. If a report was determined eligible from the title or abstract, the full article was retrieved. Potentially relevant studies chosen by at least one author were retrieved, and full-text versions were evaluated. Articles that met the inclusion criteria were assessed separately by 2 authors, and any discrepancies were resolved through discussion. If no agreement could be reached, a third investigator was involved to provide a resolution.
Inclusion and Exclusion Criteria
We included randomized controlled trials that collected data on the effectiveness of midazolam as a prophylactic agent for PONV compared with a control. Control groups were compared with an experimental group, including subjects who did not receive a drug or who received another drug, with the only difference between the groups of midazolam administration (e.g., midazolam + ondansetron versus ondansetron). The studies also included adult patients undergoing general anesthesia involving IV administration of midazolam. Data from abstracts, posters, case reports, comments, or letters to the editor, reviews, and animal studies were excluded. Studies that were not published in English were likewise excluded ( Fig. 1 ).
Study Outcomes
The primary end points were the incidence of postoperative nausea (PON), postoperative vomiting (POV), and PONV. The severity of PON was also assessed. The use of rescue antiemetics and the incidence of adverse effects, such as headache, dizziness, and sedation, were secondary outcomes in the systematic review.
Subgroup analysis was performed regardless of whether PON, POV, and PONV incidence data were collected as primary outcomes or secondary outcomes. Also, a subgroup analysis was performed to rule out the effects of propofol as an induction agent. In addition, administration times were divided into 2 phases representing the induction and conclusion of surgery. In studies with >1 midazolam group or control group, all midazolam groups or all control groups were combined to avoid a unit of analysis error.
Validity Scoring
The quality of eligible studies was assessed independently by 2 members of the review group using the "risk of bias" tool within the Review Manager software program (version 5.2, The Cochrane Collaboration, Oxford, UK). Quality was evaluated based on potential sources of bias, including random sequence generation, allocation concealment, blinding of the participants, blinding of outcome assessment, incomplete outcome data, selective reporting, and overall risk bias. The data were then cross-checked. The methodology of each trial was graded as "high," "low," or "unclear," to reflect a high risk or a low risk of bias, and uncertainty regarding the risk of bias, respectively. 17 
Data Extraction
All interrelated data from the included studies were independently extracted and entered into a spreadsheet by 2 authors, and then cross-checked. Any discrepancy was resolved through discussion. If an agreement could not be reached, the dispute was resolved with the aid of a third investigator. The spreadsheet included the following items: (1) title, (2) authors, (3) name of journal, (4) publication year, (5) study design, (6) registration of clinical trial, (7) competing interest, (8) country, (9) risk of bias, (10) number of patients in study, (11) dose of midazolam and control drugs, (12) sex, (13) age, (14) weight, (15) height of patients, (16) duration of anesthesia, (17) ASA physical status, (18) inclusion criteria, (19) exclusion criteria, (20) type of surgery, (21) airway device, (22) induction agent, (23) maintenance agent, (24) use of nitrous oxide, (25) use of an opioid during the perioperative period, (26) timing of administration of the experimental drug, (27) other drugs used during surgery, (28) timing of rescue antiemetics, (29) rescue analgesics, (30) definition of nausea, vomiting, and retching, (31) number of cases of PON, POV, and PONV overall and during the early and late postoperative phases, and (32) the need for rescue antiemetics.
The data were initially extracted from tables or text. In cases involving missing or incomplete data, an attempt was made to contact the study authors to obtain the relevant information. If the author did not respond or did not have current information, the data were extracted from available figures.
Statistical Analysis
The review and meta-analysis were conducted using Comprehensive meta-analysis software (version 2.0, Biostat, Englewood, NJ) and Review Manager software (version 5.2, The Cochrane Collaboration, Oxford, UK). For dichotomous data, a pooled risk ratio (RR) and 95% confidence intervals (CIs) were calculated. If the 95% CI included a value of 1, the difference was not considered statistically significant. We calculated the mean difference (MD) for continuous data and reported the 95% CI. If the 95% CI included a value of 0, the difference was not considered statistically significant.
We used the χ 2 test and the I 2 test for heterogeneity. If the P value was <0.10 or an I 2 value was >50%, the heterogeneity was considered significant. A fixed-effects model was selected if P value for χ 2 test >0.10 and the I 2 value was <50%. In cases with I 2 value >50%, random-effects models were used. Because all the number of combined studies that showed substantial heterogeneity were <10, t statistics (Hartung-Knapp-Sidik-Jonkman method) were used instead of Z test in all random-effects analysis to lower the error rate. A subgroup analysis was performed based on the timing of the PON, POV, and PONV assessments; the time of midazolam administration; the use of perioperative opioids; the use of propofol as an induction agent; and whether the aim of the study included PONV as a primary or secondary outcome. If heterogeneity was >50%, sensitivity analysis was likewise performed by excluding one study at a time to evaluate the influence of a single study on the overall effect estimate.
We calculated the number needed to treat (NNT) using a 95% CI based on the absolute risk reduction as an estimate of the overall clinical impact of the intervention. 18 Publication bias was identified by the Egger linear regression test, and a P value of <0.05 was used to identify the presence of a publication bias, or funnel plots for each data set were visually assessed for asymmetry. If a publication bias was present, a trim-and-fill analysis was performed to evaluate the effect of the bias.
RESULTS

Literature Search and Study Characteristics
A search of the MEDLINE, Embase, and CENTRAL databases returned 1296 studies that were initially evaluated. After excluding duplicates, 1197 studies remained. Another 1040 studies were excluded after the review of titles and abstracts. Studies that were not published in English were likewise excluded. Of the 151 studies that remained, 83 additional studies were excluded because 39 of the studies involved children and 44 studies involved administration of experimental drugs. Forty-two studies were excluded because they were performed under monitored or regional anesthesia care and not under general anesthesia. The full texts of the remaining 26 studies were reviewed in detail, and 11 additional studies were excluded because 8 did not include a control group, 15,19-25 2 administered midazolam for therapeutic management, 14, 26 and 1 did not report findings for PON, POV, or PONV. 27 Manual review of the references of the included studies identified 13 additional studies for assessment. However, only one met the inclusion criteria for the present review. 28 Collectively, 16 studies met the inclusion criteria and were included in this systematic review and meta-analysis. 6, [8] [9] [10] 12, 14, 26, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] The characteristics of the 16 studies that met the inclusion criteria are summarized in Tables 1, 2, and 3. Midazolam was administered at induction in 11 studies [8] [9] [10] 12, 29, 30, 32, 33, 35, 37, 38 and at the end of the surgery in 3 studies. 6, 28, 31 Two studies compared the timing of administration, 34,36 2 studies included a nausea visual analog scale for assessing the severity of PON, 10,32 and 3 studies did not involve administration of perioperative opioids. 12, 37, 38 Twelve of the 16 studies 6, 10, 12, 28, 29, [31] [32] [33] [34] [36] [37] [38] were aimed at comparing the incidence of PONV, and 4 studies involved the collection of PONV incidence as a secondary end point. 8, 9, 30, 35 In the studies by Park et al. 34 and Safavi and Honarmand, 36 subjects were divided into groups based on drug administration at the induction or conclusion of surgery. The group receiving midazolam or placebo administration at induction was designated Park1 and Safavi1, respectively, and the groups receiving the drugs at the end of surgery were designated Park2 and Safavi2, respectively. To avoid duplicate counting, the groups were divided in both studies.
In the study by Honarmand et al., 6 4 separate cohorts received haloperidol, midazolam, haloperidol plus midazolam, or saline. Similarly, 4 separate cohorts in the study conducted by Makhdoom and Farid 33 received dexamethasone, midazolam, dexamethasone plus midazolam, or saline. Therefore, comparison of midazolam with a placebo was designated Honarmand1 and Makhdoom1, respectively, and the comparison of midazolam plus another drug with the second drug was designated Honarmand2 and Makhdoom2, respectively.
The postoperative period was divided into the overall, early, and late phases. The early phase was defined as 0 to 6 hours postoperatively, and the late phase as 6 to 24 hours postoperatively. The overall phase was included to capture the maximal number of studies that contained PON, POV, and PONV data with a variable data collection period and was defined as the first period of data collection (Table 4 ).
Because several studies defined the early and late phase differently, we combined the earliest period of data collection with early incidence of PON, POV, PONV, and severity of PON. For the early phase, 3 studies included postanesthesia care unit data, 8, 28, 30 4 studies included data collected at 0 to 2 hours, 32, 34, 36, 37 and 1 study collected data at 0 to 60 minutes. 35 In addition, the widest overlapping period of data collection for late incidence of PON, POV, PONV, and late PON severity was combined. For the late phase, one study included data from 8 to 14 hours, 10 a second study contained 2-to 24-hour data, 34 3 studies reported 6-to 12-hour data, 32, 36, 37 and 1 additional study included 6-to 24-hour data. 28 
Risk of Bias
Fifteen studies referenced the random sequence generation method, 6,8-10,12,29-38 and only 2 studies described allocation concealment. 32, 34 In every study, outcome assessors were blinded, and no incomplete data were reported. The overall risks of bias are shown in Table 5 .
Postoperative Nausea
Overall, Early, and Late PON Eleven studies compared the effectiveness of midazolam in preventing overall PON with those of a placebo or another drug. 8, 9, 12, [29] [30] [31] [33] [34] [35] 37, 38 Five studies compared its effectiveness in reducing the incidence of early PON, 8, 30, 34, 35, 37 and 2 studies compared its effects on late PON. 34, 37 Analysis of the combined results revealed that midazolam was associated with a statistically significant reduction in the overall incidence of PON (risk ratio [RR], 0.51; 95% CI, 0.40-0.65; I 2 = 35%; P χ 2 = 0.10; NNT = 6; number of included studies [n] = 11) compared with the control groups. However, the effect of midazolam on the incidence of early and late PON compared with the control groups is unknown (RR, 0.56; 95% CI, 0.17-1.82; P χ 2 = 0.069; I 2 = 51%; NNT = 7; n = 5; and RR, 0.74; 95% CI, 0.42-1.31; P χ 2 = 0.14; I 2 = 49.7%; NNT = 11; n = 2, respectively).
Effect of Administration Timing on Overall PON
Nine studies 8, 12, 29, 30, [33] [34] [35] 37, 38 analyzed the effectiveness of midazolam administered at induction of surgery in preventing overall PON, whereas 2 studies 31,34 assessed its effectiveness after administration at the conclusion of surgery. The combined results of both analyses indicated that midazolam caused a statistically significant reduction in the incidence of overall PON, regardless of the timing of administration (RR, 0.53; 95% CI, 0.39-0.71; I 2 = 31%; P χ 2 = 0.16; NNT = 7; n = 9; and RR, 0.30; 95% CI, 0.14-0.66; I 2 = 0%; P χ 2 = 0.61; NNT = 4; n = 2, respectively; Fig. 2 ).
Severity of PON
Two studies 10,32 compared the effects of midazolam on the severity of PON using a visual analog scale score. The postoperative periods of the 2 studies were divided into the early phase (0-6 hours after surgery) and the late phase (6-24 hours after surgery). However, we were not able to clarify the effect on the severity of PON after administration of midazolam in the early or late postoperative phases when compared with a placebo (MD, −0.38; 95% CI, −3.39 to 2.64; I 2 = 77.2%; P χ 2 = 0.036; n = 2; and MD, −0.04; 95% CI, −0.71 to 0.62; I 2 = 0%; P χ 2 = 0.39; n = 2, respectively). 
Effect of Midazolam in Conjunction with Propofol as an Induction Agent on Overall PON
Seven studies 8, 9, 12, 30, 31, 35, 38 evaluated the effectiveness of midazolam in reducing overall PON with the use of propofol as an induction agent, whereas 3 studies 33,34,37 assessed its effectiveness without propofol. The combined results of both analyses revealed that midazolam caused a statistically significant reduction in the incidence of overall PON, regardless of propofol administration (RR, 0.64; 95%, CI 0.47-0.87; I 2 = 45%; P χ 2 = 0.09; NNT = 9; n = 7; and RR, 0.39; 95% CI, 0.23-0.65; I 2 = 35%; P χ 2 = 0.19; NNT = 5; n = 3, respectively).
Data Collected as Primary or Secondary
Outcomes PON incidence was collected as a primary end point in 7 studies, 12, 29, 31, 33, 34, 37, 38 whereas 4 studies 8, 9, 30, 35 collected PON incidence as a secondary end point. The combined results of both analyses regarding primary and secondary outcomes revealed that midazolam caused a statistically significant reduction in the overall incidence of PON, regardless of the aim of the study (RR, 0.46; 95% CI, 0.34-0.63; I 2 = 5%; P χ 2 = 0.39; NNT = 5; n = 7; and RR, 0.64; 95% CI, 0.44-0.93; I 2 = 42%; P χ 2 = 0.16; NNT = 8; n = 4, respectively).
Postoperative Vomiting
Overall, Early, and Late POV Ten studies assessed the effects of midazolam on the overall POV, 10, 12, [29] [30] [31] [32] [33] [34] 37, 38 whereas 4 studies compared the effects on the incidence of early POV, 30, 32, 34, 37 and 3 studies evaluated its effects on the incidence of late POV. 32, 34, 37 The combined results revealed that midazolam caused a statistically significant reduction in the incidence of overall POV (RR, 0.46; 95% CI, 0.33-0.65; I 2 = 0%; P χ 2 = 0.87; NNT = 8; n = 10; Fig. 3 ). Also, the results suggest the beneficial effect of midazolam on the incidence of early or late POV when compared with a placebo, but these did not reach the statistical significance (RR, 0.48; 95% CI, 0.22-1.01; I 2 = 0%; P χ 2 = 0.54; NNT = 16; n = 4; and RR, 0.40; 95% CI, 0.13-1.27; I 2 = 0%; P χ 2 = 0.85; NNT = 23; n = 3, respectively).
Effect of Administration Timing on Overall POV
Eight studies 10, 12, 29, 30, [32] [33] [34] 37 assessed the effects of midazolam on the overall POV when administered at induction, and 2 studies 31,34 assessed the effects of midazolam administered at the conclusion of surgery. The combined results revealed that midazolam administered at induction caused a statistically significant reduction in the incidence of overall POV (RR, 0.45; 95% CI, 0.31-0.65; I 2 = 0%; P χ 2 = 0.61; I 2 = 0%; NNT = 7; n = 8). Also, the effect of midazolam administered at the end of surgery showed the tendency of reduction in the incidence of overall POV (RR, 0.49; 95% CI, 0.20-1.19; I 2 = 0%; P χ 2 = 0.56; NNT = 8; n = 2).
Effect of Midazolam in Conjunction with Propofol as an Induction Agent on Overall POV
Four studies 12, 30, 31, 38 assessed the effectiveness of midazolam administered with propofol as an induction agent in preventing overall PON, whereas 5 studies 14,32-34,37 assessed its effectiveness without propofol. The combined results of both analyses revealed that midazolam caused a statistically significant reduction in the incidence of overall PON, regardless of propofol administration (RR, 0.37; 95% CI, 0.20-0.68; I 2 = 0%; P χ 2 = 0.42; NNT = 8; n = 4; and RR, 0.54; 95% CI, 0.35-0.84; I 2 = 0%; P χ 2 = 0.87; NNT = 8; n = 5, respectively).
Data Collected as Primary or Secondary Outcomes
Nine studies 10, 12, 29, [31] [32] [33] [34] 37, 38 collected the incidence of POV as a primary end point, whereas only 1 study 30 collected POV incidence as a secondary end point. The results of the combined analysis revealed that midazolam caused a statistically significant reduction in the overall incidence of POV as a primary outcome (RR, 0.48; 95% CI, 0.34-0.68; I 2 = 0%; P χ 2 = 0.90; NNT = 8; n = 9). However, the analysis of POV incidence as a secondary end point could not be performed because of the small number of studies included.
Postoperative Nausea and Vomiting
Overall, Early, and Late PONV Seven studies assessed the effects of midazolam on overall PONV, 6, 12, 31, 33, [36] [37] [38] 4 investigations compared the effects on the incidence of early PONV, 6, 32, 34, 36 and 2 studies evaluated the effects on the incidence of late PONV. 28, 36 The combined results revealed that midazolam caused a statistically significant reduction in the incidence of overall, early, and late PONV (RR, 0.45; 95% CI, 0.36-0.57; I 2 = 31%; P χ 2 = 0.16; NNT = 3; n = 7; RR, 0.50; 95% CI, 0.32-0.79; I 2 = 30%; P χ 2 = 0.22; NNT = 6; n = 4; Method of estimating overall risk of bias: If all results or the above items were "low risk," the overall risk of bias of the trial was deemed to be low risk of bias. If more than one of the above items were "unclear" or " high risk," the overall risk of bias of the trial was deemed to be unclear risk of bias or high risk of bias, respectively. High risk = high risk of bias; low risk = low risk of bias; unclear risk = unclear risk of bias because of lack of detailed reports.
and RR, 0.26; 95% CI, 0.12-0.59; I 2 = 43%; P χ 2 = 0.17; NNT = 5; n = 2, respectively; Fig. 4 ).
Effect of Administration Timing on Overall PONV
Five studies 12, 33, [36] [37] [38] assessed the effects of midazolam on overall PONV after administration at surgical induction, and 3 investigations 6,28,36 assessed its effectiveness at the end of surgery. The combined results indicated that midazolam administration at both the induction and the conclusion of surgery caused statistically significant reductions in the incidence of overall PONV (RR, 0.44; 95% CI, 0.33-0.59; I 2 = 24%; P χ 2 = 0.25; NNT = 3; n = 5; and RR, 0.50; 95% CI, 0.31-0.78; I 2 = 48%; P χ 2 = 0.12; NNT = 4; n = 3, respectively).
Effects on Overall PONV With or Without Perioperative Opioids
Five studies 6, 28, 31, 33, 36 compared the effectiveness of midazolam in reducing the overall PONV in combination with perioperative opioids, and 3 studies 12,37,38 compared its effectiveness without perioperative opioids. The combined results revealed that midazolam administered with perioperative opioids caused a statistically significant reduction in the incidence of overall PONV (RR, 0.43; 95% CI, 0.32-0.59; I 2 = 1%; P χ 2 = 0.42; NNT = 3; n = 5). Also, midazolam administered without perioperative opioids showed beneficial effect on the incidence of overall PONV, but this did not reach the statistical significance (RR, 0.46; 95% CI, 0.10-2.12; I 2 = 66.4%; P χ 2 = 0.05; NNT = 3; n = 3).
Effect of Midazolam in Conjunction with Propofol as an Induction Agent on Overall PONV
Four studies 12, 31, 36, 38 analyzed the effectiveness of midazolam in reducing the overall PONV when used in conjunction with propofol as an induction agent, whereas 4 separate studies 6, 28, 33, 38 assessed its effectiveness without the administration of propofol as an induction agent. The combined results of both analyses revealed that midazolam caused a statistically significant reduction in the incidence of overall PON independent of propofol administration (RR, 0.48; 95% CI, 0.36-0.65; I 2 = 9%; P χ 2 = 0.35; NNT = 3; n = 4; and RR, 0.41; 95% CI, 0.29-0.57; I 2 = 42%; P χ 2 = 0.12; NNT = 3; n = 4, respectively).
Rescue Antiemetics
Eleven studies 9, 12, 28, 29, [31] [32] [33] [34] [35] [36] 38 compared the requirement for rescue antiemetics among midazolam recipients and controls. The combined results revealed statistically significant differences in the requirement for rescue antiemetics, but with substantial heterogeneity (RR, 0.52; 95% CI, 0.37-0.74; I 2 = 53%; P χ 2 = 0.009; NNT = 5; n = 11). Exclusion of the study by Gilliland et al. 9 before a sensitivity analysis revealed a decrease in heterogeneity and a statistically www.anesthesia-analgesia.org
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Meta-Analysis for Midazolam and PONV significant reduction in the requirement for rescue antiemetics (RR, 0.44; 95% CI, 0.34-0.56; I 2 = 0%; P χ 2 = 0.67; NNT = 4; n = 10). In addition, the same outcome was observed when the study by Yeo et al. 38 was excluded (RR, 0.57; 95% CI, 0.45-0.71; I 2 = 47%; P χ 2 = 0.03; NNT = 5; n = 10).
Effect of Midazolam in Conjunction with Propofol as an Induction Agent in the Requirement for Rescue Antiemetics
The effectiveness of midazolam with propofol as an induction agent in cases requiring rescue antiemetics was analyzed in 6 studies. 9, 12, 31, 35, 36, 38 Four studies 28, [32] [33] [34] assessed the effectiveness of midazolam without the use of propofol as an induction agent. The combined results of combined analyses indicated that midazolam with propofol as an induction agent showed no evidence of difference in the use of rescue antiemetics (RR, 0.54; 95% CI, 0.024-1.09; P χ 2 = 0.002; I 2 = 72%; NNT = 7; n = 6). Conversely, the effects of midazolam on the requirement for rescue antiemetics without propofol revealed statistically significant reductions without heterogeneity (RR, 0.50; 95% CI, 0.31-0.79; I 2 = 0%; P χ 2 = 0.84; NNT = 7; n = 4).
Data Collected as Primary or Secondary Outcomes
Seven studies 6, 12, 31, 33, [36] [37] [38] collected the incidence of PONV as a primary end point, but there were no studies that collected PONV incidence as a secondary end point. The results of the combined analysis revealed that midazolam caused a statistically significant reduction in the overall incidence of PONV as a primary outcome (RR, 0.45; 95% CI, 0.36-0.57; I 2 = 31%; P χ 2 = 0.16; NNT = 3; n = 7).
Safety Analysis
Headache The incidence of headaches among midazolam recipients was compared with controls in 4 studies. 6, 12, 34, 38 The analysis of the combined findings showed a neutral result (RR, 1.18; 95% CI, 0.56-2.49; I 2 = 0%; P χ 2 = 0.86; NNT = 1045; n = 4).
Dizziness
The overall effect of midazolam on the incidence of dizziness was assessed in 4 studies, 12, 31, 34, 38 but there was no statistically significant effect of midazolam relative to the placebo (RR, 0.90; 95% CI, 0.46-1.77; I 2 = 0; P χ 2 = 0.79; NNT = 53; n = 4).
Sedation
The overall effect of midazolam on the incidence of postoperative sedation was assessed in 4 studies, 9, 12, 31, 34 but there were no statistically significant effect (RR, 1.33; 95% CI, 0.65-2.71; I 2 = 58%; P χ 2 = 0.04; NNT = 15; n = 4).
Publication Bias
Evidence of a publication bias was detected by the Egger linear regression test (P < 0.05; Table 4 ). Similarly, the funnel plot analyses for these values demonstrated asymmetry ( Fig. 5 ). However, the funnel plots became symmetrical after adjustment using the trim-and-fill method (Fig. 5 ). The results before and after elimination of the effect of publication bias are shown in Table 6 . The significance of the RR with 95% CIs did not change after the elimination of the publication bias.
DISCUSSION
The results of the current study suggested that midazolam reduced the overall incidence of PON, POV, and PONV, with an NNT of 3 for overall PONV. Furthermore, the results indicated that midazolam treatment can prevent nausea and vomiting in approximately 1 in 3 patients who would otherwise continue to suffer from PONV if administered a placebo. 18 In addition, the need for rescue antiemetics was reduced among patients in the midazolam groups compared with control groups, and no evidence found that midazolam was associated with adverse effects, such as headache, dizziness, or sedation.
Midazolam was shown to have a preventive effect on PONV in the early, late, and overall recovery period and was also effective in preventing overall PON and POV. However, we were not able to clarify the effects of midazolam on the early and late recovery period of PON or POV. The combined results of early and late PON were considerably heterogeneous, otherwise there was no substantial heterogeneity in POV. It seems that subjective judgments of feeling nausea lead to a large variation among collected data, unlike vomiting.
The combined results of 2 studies indicated that midazolam appeared to be effective in preventing late PONV. However, 1 of the 2 studies 28 administered midazolam as a continuous patient-controlled analgesia infusion, which might have adversely affected the results. Therefore, further studies are needed to evaluate the duration of the antiemetic effect. In addition, many patients currently receive antiemetics as opposed to no treatment. Therefore, further studies or a systematic review comparing midazolam with other antiemetics would be needed to confirm the potency of the antiemetic effects of midazolam.
Preoperative anxiety may increase gastric acid secretion, lower gastric pH, and delay gastric emptying, which leads to an increase in PONV. 29 However, several studies reported that anxiety was not related to the incidence of PONV. [39] [40] [41] In addition, the consensus guidelines for the management of PONV 42 state that in adults, anxiety is not a proven risk factor and may be of limited clinical relevance. In the study conducted by Safavi and Honarmand, 36 the incidence of PONV was significantly lower among subjects who received midazolam at induction compared with those who received the agent at the end of surgery. However, Park et al., 34 reported that no significant differences were observed between administration of midazolam at induction or at the end of surgery. In this meta-analysis, a statistically significant reduction in the incidence of PON, POV, and PONV relative to controls was observed after midazolam administration at induction. However, only the incidence of PON was significantly reduced after administration of midazolam at the end of surgery when compared with the control group. This would imply that the anxiolytic effect of midazolam may be important in its PONV efficacy, which is not in accord with the consensus guidelines.
In the study by Splinter et al., 43 a 50 to 75 μg/kg midazolam dose was recommended for prophylactic antiemetic use. In the current meta-analysis, the doses of midazolam in the reviewed studies ranged from 35 to 75 μg/kg. However, the 35 to 75 μg/kg dosing range might be an excess of quantity for preventing PONV with the risk of sedation. Therefore, when using midazolam, which is a hypnotic agent, the sedative effects, respiratory depression, and prolonged recovery time might be a major safety concern. However, no significant differences were apparent between midazolam and control groups after a safety analysis, but the different sedation scoring scales in the studies limited the combination of data. Fifteen of the 16 relevant studies reported that there were no significant differences between midazolam and control groups. Among 3 studies in which midazolam was administered continuously, 9, 28, 31 only 1 study 31 reported that the incidence of mild sedation in the midazolam group was higher than levels in the control group. However, the incidence of moderate to severe sedation or respiratory depression was not observed in any group.
A subgroup analysis was performed to evaluate the effects of midazolam administration on PONV when used in conjunction with propofol as an induction agent. The results of the analysis indicated that midazolam had a statistically significant effect on overall PON, POV, and PONV whether propofol was administered or not. However, the requirement for rescue antiemetics showed no evidence when propofol was used in conjunction with midazolam as an induction agent. Conversely, the requirement for rescue antiemetics revealed a significant reduction compared with the control group when only midazolam was used as an induction agent without propofol. We suggest that the use of propofol, which has been reported to decrease the incidence of early PONV, 44, 45 might have affected the requirement for rescue antiemetics.
Nonetheless, an apparent publication bias was evident in several comparisons of midazolam and controls in the current study and may have influenced the results. Nevertheless, the significance of the study findings was not altered after consideration of the apparent publication bias. Consequently, we had confidence in our findings, despite the omission of data from unpublished studies.
To include maximum data regarding the antiemetic effects of midazolam, several studies contained PONV data as an inevitable secondary end point, which might have increased the likelihood that confounding variables influenced the results. Therefore, we performed a subgroup analysis based on whether PON, POV, and PONV incidence data were collected as primary or secondary outcomes. The combined results of the analyses revealed that midazolam caused a statistically significant reduction in the incidence of overall PON, regardless of the aim of the studies.
The current study has several limitations. First, only published studies were included in our meta-analysis. Second, only 2 studies included the late effectiveness of midazolam on PONV, one of which included the continuous infusion of midazolam using a patient-controlled analgesia device. Third, many studies either did not assess side effects or adverse events or approached them in different ways. Hence, the late effectiveness of midazolam on PONV and the results of safety analyses should be interpreted cautiously. Despite its limitations, the present meta-analysis demonstrated strength through the application of rigorous methodology and provided the first systematic review assessing the prophylactic effect of midazolam on the incidence of PONV. Moreover, added strengths of our study included the large sample size, the thorough identification of articles, the data extraction, and the resolution of all discrepancies by 3 independent investigators. Furthermore, our subgroup and sensitivity analyses yielded stable and robust findings. In summary, the prophylactic administration of midazolam reduced the incidence of overall PON, POV, and PONV. Furthermore, the effects were more evident during the early postoperative phase than during the late phase, and the reductions in the incidence of PON, POV, and PONV were greater when midazolam was administered at the induction of surgery. E APPENDIX Medline
